| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor target(s) | GLP-1R | GIPR + GLP-1R (dual) |
| Backbone | GLP-1 (7-37) analog, 31 aa | GIP-derived, 39 aa |
| Lipidation | C18 fatty di-acid | C20 fatty di-acid |
| CAS | 910463-68-2 | 2023788-19-2 |
| Elev8 format | 5MG lyophilized vial | 10MG lyophilized vial |
| Typical models | GLP-1 pathway, islet signalling | Dual-incretin, energy balance |
What separates them
The core distinction is receptor coverage. Semaglutide is a selective GLP-1 receptor agonist, which makes it the cleaner tool for isolating GLP-1R signalling. Tirzepatide engages both the GIP and GLP-1 receptors with a reported bias toward GIPR, which is why it is chosen for studies comparing single- versus dual-incretin activation.
Practical lab differences
- Both are lyophilized and reconstituted with bacteriostatic water.
- Both carry lipid side chains; avoid vigorous agitation during reconstitution to limit aggregation.
- Confirm concentration from the batch COA rather than the label nominal where precise molarity matters.